Atrial Fibrillation (AFib) is a common heart rhythm disorder that places a significant burden on patients and healthcare systems. The condition --which affects over 33 million people worldwide1 -- is challenging the medical community to provide care, awareness, and education in more effective and efficient ways.
In 2002, Biosense Webster Inc. established the AFib Symposium as an annual forum to deliver practical and scientific learning to the European Electrophysiology (EP) community. This year, due to COVID 19, the program has been re-imagined for a virtual setting. By leveraging the digital learning expertise of the Johnson & Johnson Institute, it will provide a flexible education and training experience that engages participants at various touchpoints throughout the year. You can join the conversation by following and using the symposium hashtag #AFIB2021 on social media.
Global Experts Host Scientific Session in March
On March 18, an international faculty of experts will present the newest developments, research, and perspectives in AFib treatment. The online event will combine live sessions and pre-recorded content in an engaging format for those seeking to advance their knowledge and practice. The registration for the event is not intended for US healthcare providers (HCPs) due to regulatory limitations. The content of the event is aimed at HCPs outside of the US. You can learn more about the scientific program here.
Practical Learning Delivered Remotely
New technologies and techniques have revolutionized AFib treatment. Each year, the Practical Sessions of the AFib Symposium focus on all aspects of cardiac ablation procedures and the use of new technologies. The legacy will continue when the first part of the 2021 Practical Sessions is held virtually on May 22. Through interactive live demonstrations and roundtable discussions, expert faculty will share their insights for improving procedure workflow, safety, efficiency and ultimately, quality of care. You can learn more here https://jnjinstitute.com/en-emea/events/afib-2021-evidence-based-directions-afib-therapy
“Virtual conferences can be more inclusive and better accommodate the work/life commitments of participants around the world,” said Tamer Shawky, Senior Director, Education Solutions CSS EMEA. “We are grateful to our faculty for their leadership and collaboration with this year’s symposium and look forward to providing an enriching learning experience to advance the treatment of AFib.”
1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.
© Johnson & Johnson Medical NV/SA 2021. EMEA. All rights reserved. 169069-210303